Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

Adults with a mental illness experienced weight loss and glycemic benefits with use of a GLP-1 without worsening of mental ...

President Donald Trump imposed a minimum tariff of 10% on almost all countries, before later suspending the measures ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...